Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Amitriptyline improves functional dyspepsia symptoms

03 Mar 2018

Antidepressants, particularly amitriptyline, appear to be effective in improving functional dyspepsia (FD) symptoms but not in delaying gastric emptying, a recent study has shown.

Researchers randomized 292 FD patients to receive 50 mg of amitriptyline (AMI), 10 mg of escitalopram (ESC) or matching placebo over a 12-week trial period. Majority of patients (53 percent) who received AMI showed global improvements in FD symptoms, as opposed to only 38 percent in the ESC and 50 percent in the placebo groups. The among-difference was of borderline significance (p=0.054).

While none of the treatment groups had a significant impact on maximal-tolerated volume in the nutrient drink test (MTV), aggregate symptom scores, which included abdominal pain, fullness and bloating, were significantly better in both the AMI and ESC group relative to placebo (p=0.04).

In terms of individual symptoms, antidepressant therapy significantly improved both bloating 30 minutes after nutrient drink test (p=0.04) and abdominal pain (p=0.09) relative to placebo. Amitriptyline was significantly better than escitalopram for abdominal pain.

Antidepressant therapy also significantly increased postprandial gastric volume (p=0.02), and the effect remained significant even when restricted to AMI (p<0.01) or ESC (p=0.05) groups only, as compared with the placebo group. AMI and ESC were statistically comparable in terms of postprandial gastric volume (p=0.37). Fasting gastric volume was unaffected by antidepressant therapy (p=0.66).

Baseline delayed gastric emptying was reported in 21 percent of the participants. None of the treatments resulted in significantly altered gastric emptying.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.